NewLink Genetics Corp(NLNK)stock report

The Newlink Genetics Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of immunotherapy products to improve treatment options for cancer patients. The company’s products include biological and small molecule immunotherapy products. The company’s biological products are based on the company’s proprietary hyperacute immunotherapy technology, which aims to stimulate the human immune system. The company’s small-molecule products focus on breaking the cancer immune system’s tolerance by inhibiting the indoleamine -(2, 3) -plus dioxygenase pathway. The company believes its immunotherapy technology has the potential to produce multiple products for a wide range of cancer symptoms that can be treated alone or in combination with other therapies. The company was incorporated in Delaware on June 4, 1999 as the NewLink Genetics Corporation.

Q3 2019(9/30/19): Cash 98.53M. Loss 14.54M

EPS and Sales:

Date EPS % last year % last quarter
2018.12.31 -1.44 37.39% -24.14%
2019.3.31 -0.27 44.90% 81.25%
2019.6.30 -0.54 43.75% -100.00%
2019.9.30 -0.93 19.83% -72.22%


Date Sales % last year % last quarter
2018.12.31 12.47M -56.55% 1.63%
2019.3.31 0.11M -98.93% -99.12%
2019.6.30 0.26M -97.89% 136.36%
2019.9.30 0.5M -95.90% 92.31%


Insider Transactions:

Institution Ownership:

Total institutions: 83,no change
Shares hold: 10356k shares. no change
shares% hold: 27.75%,no change

Analyst Ratings:

Leave a Reply